Company intelligence / Profile preview
AlloCure
Burlington, Massachusetts, United Statesdnb.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Phase 3
01
Overview
AlloCure developed AC607, an off-the-shelf allogeneic MSC therapy for acute kidney injury. The company completed a successful Phase I trial showing safety and encouraging efficacy signals. A large multicenter randomized double-blind placebo-controlled Phase II trial was launched to further evaluate efficacy in post-cardiac surgery AKI patients. No approved therapies exist for AKI beyond supportive care at the time of these studies. The company received FDA Fast Track designation for AC607 in this indication. As of the latest reports, no commercial product has been launched.
- Therapeutic areas
- OtherNephrology
- Modalities
- Cell therapyspecifically allogeneic mesenchymal stem cells (MSCs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Academic institutions/hospitals participating in ACT-AKI multicenter trial
Beyond the preview
Go deeper on AlloCure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlloCure.